Literature DB >> 2965128

Pharmacokinetics of 14C-teicoplanin in healthy volunteers.

G Buniva1, A Del Favero, A Bernareggi, L Patoia, R Palumbo.   

Abstract

Five healthy male volunteers received over 60 sec a single intravenous injection of 400 mg of teicoplanin labelled with 41 microCi of 14C. Plasma and urine total radioactivity was measured up to 10 and 16 days, respectively. Teicoplanin was assayed in plasma and urine also by a microbiological method, with similar results. Pharmacokinetic parameters were estimated by model-independent analysis and the following mean values were obtained: elimination half-life 77 h; total body clearance 9.8 ml/h/kg; renal clearance 7.81 ml/h/kg; volume of distribution at steady-state 0.759 l/kg. Similar estimates were obtained by a compartmental analysis. A total of 80% of the administered dose was recovered in urine in 16 days; 2.7% of the dose was recovered in faeces collected for eight days after administration. The mean total recovery of the drug was 83 +/- 0.6%. The plasma and urine concentrations of teicoplanin observed after a single 400 mg iv dose exceeded the MIC for most pathogens for at least one day, and this suggests that a daily dosage regimen would be satisfactory for patients with normal renal function.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2965128     DOI: 10.1093/jac/21.suppl_a.23

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  12 in total

Review 1.  A risk-benefit assessment of teicoplanin in the treatment of infections.

Authors:  F de Lalla; A Tramarin
Journal:  Drug Saf       Date:  1995-11       Impact factor: 5.606

2.  Teicoplanin metabolism in rats.

Authors:  L F Zerilli; L Cavenaghi; A Bernareggi; A Assandri
Journal:  Antimicrob Agents Chemother       Date:  1989-10       Impact factor: 5.191

Review 3.  Clinical pharmacokinetics of teicoplanin.

Authors:  M Rowland
Journal:  Clin Pharmacokinet       Date:  1990-03       Impact factor: 6.447

Review 4.  Teicoplanin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential.

Authors:  D M Campoli-Richards; R N Brogden; D Faulds
Journal:  Drugs       Date:  1990-09       Impact factor: 9.546

5.  Pharmacokinetics of individual components of teicoplanin in man.

Authors:  A Bernareggi; A Danese; A Cometti; G Buniva; M Rowland
Journal:  J Pharmacokinet Biopharm       Date:  1990-12

6.  Teicoplanin pharmacokinetics in healthy volunteers after administration of intravenous loading and maintenance doses.

Authors:  W R Outman; C H Nightingale; K R Sweeney; R Quintiliani
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

7.  Teicoplanin plus ciprofloxacin versus gentamicin plus piperacillin in the treatment of febrile neutropenic patients.

Authors:  S M Kelsey; B Weinhardt; P W Collins; A C Newland
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-06       Impact factor: 3.267

8.  Efficacy and pharmacokinetics of teicoplanin in hemodialysis patients.

Authors:  B Beckers; H P Brodersen; R M Stolpmann; G Jansen; D Larbig
Journal:  Infection       Date:  1993 Jan-Feb       Impact factor: 3.553

9.  Teicoplanin metabolism in humans.

Authors:  A Bernareggi; A Borghi; M Borgonovi; L Cavenaghi; P Ferrari; K Vékey; M Zanol; L F Zerilli
Journal:  Antimicrob Agents Chemother       Date:  1992-08       Impact factor: 5.191

10.  Pharmacokinetics and tolerability of teicoplanin in healthy volunteers after single increasing doses.

Authors:  A Del Favero; L Patoia; R Rosina; G Buniva; A Danese; A Bernareggi; E Molini; L Cavenaghi
Journal:  Antimicrob Agents Chemother       Date:  1991-12       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.